Neurofibromatosis and Schwannoma Cases
Research Guide

The NF1 gene is a large transcript disrupted in Neurofibromatosis Type 1 patients, located on chromosome 17. Wallace et al. (1990) identified it through analysis of patient samples, confirming its role in the autosomal dominant disorder affecting neural crest-derived tissues. No reliable cellular phenotypic marker existed prior to this identification.

The NF2 gene encodes a putative membrane-organizing protein, and its alteration causes Neurofibromatosis Type 2 with schwannomas. Rouleau et al. (1993) demonstrated mutations in this gene from NF2 patient samples. Trofatter et al. (1993) identified it as a moesin-, ezrin-, radixin-like gene serving as the NF2 tumor suppressor.

Malignant peripheral nerve sheath tumors (MPNST) occurred in 120 cases reviewed over 71 years, with 52 males and 68 females at a mean age of 35.3 years. Ducatman et al. (1986) reported 12 patients under 20 years, highlighting the clinicopathologic features. These tumors associate with neurofibromatosis cases.

Von Recklinghausen Neurofibromatosis, or NF1, involves tumors from neural crest origins and relates to genetics and cancer research. Riccardi (1981) emphasized its importance to thousands of patients and disciplines like melanin synthesis and cell interactions. Recent gene identification advanced understanding.

Tumor suppressor genes like NF1 and NF2 are disrupted in Neurofibromatosis, leading to schwannomas and neurofibromas. Wallace et al. (1990) and Rouleau et al. (1993) identified specific gene alterations in patients. These findings underpin molecular mechanisms of Schwann cell tumors.